Markets:

Overview

News

Currencies

International

Treasuries

Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

1.611 +0.041 (+2.59%)

Streaming Delayed Price Updated: 1:23 PM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Caribou Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold ↗

February 26, 2024

Buy this stock if you're daring, but avoid it for now if you aren't.

Via The Motley Fool

Caribou Biosciences to Participate in Upcoming Investor Conferences

February 15, 2024

From Caribou Biosciences, Inc.

Via GlobeNewswire

2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare ↗

February 12, 2024

It's less scary to take on risky investments when the market is rising.

Via The Motley Fool

3 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

January 15, 2024

These companies are still in the early innings of their growth potential.

Via The Motley Fool

Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024

January 07, 2024

From Caribou Biosciences, Inc.

Via GlobeNewswire

Where Caribou Biosciences Stands With Analysts ↗

July 26, 2023

Via Benzinga

3 Gene-Editing Stocks With the Potential to Mint Millionaires ↗

December 13, 2023

Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR.

Via InvestorPlace

Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

December 12, 2023

From Caribou Biosciences, Inc.

Via GlobeNewswire

Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy ↗

December 07, 2023

These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases.

Via InvestorPlace

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗

December 04, 2023

The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.

Via The Motley Fool

Ross Stores Reports Strong Earnings, Joins Buckle, Twist Bioscience And Other Big Stocks Moving Higher On Friday ↗

November 17, 2023

U.S. stocks traded mostly lower, with the Dow Jones falling over 20 points on Friday.

Via Benzinga

Topics Stocks

Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

November 07, 2023

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board

November 06, 2023

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

November 01, 2023

From Caribou Biosciences, Inc.

Via GlobeNewswire

Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

November 06, 2023

Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge...

Via Benzinga

2 Top Growth Stocks to Buy Right Now Without Hesitation ↗

October 20, 2023

These stocks are dirt cheap right now.

Via The Motley Fool

Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

October 18, 2023

From Caribou Biosciences, Inc.

Via GlobeNewswire

2 Exciting Biotech Stocks to Buy With Less Than $10 ↗

October 11, 2023

You can pick up these stocks for a song right now.

Via The Motley Fool

Big Pharma Could Transform Into BioTech Pharma ↗

October 10, 2023

As the word itself says, biotechnology is simply technology based on biology. It uses the knowledge of cellular and biomolecular processes to develop technologies that improve our lives and overall...

Via Benzinga

A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip ↗

October 10, 2023

Wall Street price targets suggest this stock can rocket more than 400% higher.

Via The Motley Fool

2 Magnificent Growth Stocks to Buy On the Dip ↗

September 27, 2023

It might be time to catch these falling knives.

Via The Motley Fool

Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer

September 27, 2023

From Caribou Biosciences, Inc.

Via GlobeNewswire

1 Gene Editing Stock to Buy Now, and 1 to Sell ↗

September 23, 2023

Target markets matter. So does having the cash to get to them.

Via The Motley Fool

Canopy Growth, DocGo And Other Big Stocks Moving Lower On Monday ↗

September 18, 2023

U.S. stocks traded mostly flat on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Caribou Biosciences to Participate in Upcoming Investor Conferences

August 29, 2023

From Caribou Biosciences, Inc.

Via GlobeNewswire

3 Clever Tricks to Find Winning Biotech Stocks ↗

August 24, 2023

You'll need to dig into company details, but the effort is worthwhile.

Via The Motley Fool

Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

August 08, 2023

From Caribou Biosciences, Inc.

Via GlobeNewswire

3 Reasons Why Caribou Biosciences Is a Screaming Buy in July and Beyond ↗

July 28, 2023

Early-stage biotechs almost never warrant this level of enthusiasm.

Via The Motley Fool

NXP Semiconductors To Rally Over 19%? Here Are 10 Other Analyst Forecasts For Wednesday ↗

July 26, 2023

HC Wainwright & Co. cut the price target for Caribou Biosciences, Inc. (NASDAQ: CRBU) from $25 to $23. HC Wainwright & Co. analyst Robert Burns maintained a Buy rating. Caribou Biosciences shares fell...

Via Benzinga

This 1 Innovation Could Make These 2 Biotechs Soar by 2030 ↗

July 22, 2023

Simplifying the cell therapy manufacturing process could be worth a lot of money.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

All News about Caribou Biosciences, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today